Literature DB >> 19429512

Medicinal chemistry strategies in follow-on drug discovery.

Hongyu Zhao1, Zongru Guo.   

Abstract

Drug discovery targeting novel mechanisms has become extremely expensive and risky. The annual first-in-class drug approvals have not been satisfactory in the past decade (two to six per year) despite an increased R&D budget. Follow-on programs targeting proven mechanisms are less risky and costly but can produce drugs with meaningful differentiations and thus can play an important supporting role. This article will discuss the medicinal chemistry strategies that have been utilized by the pharmaceutical industry to exploit validated therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429512     DOI: 10.1016/j.drudis.2009.02.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  3 in total

Review 1.  Primaquine derivatives: Modifications of the terminal amino group.

Authors:  Branka Zorc; Ivana Perković; Kristina Pavić; Zrinka Rajić; Maja Beus
Journal:  Eur J Med Chem       Date:  2019-08-23       Impact factor: 6.514

2.  Synthesis and Biological Evaluation of Harmirins, Novel Harmine-Coumarin Hybrids as Potential Anticancer Agents.

Authors:  Kristina Pavić; Maja Beus; Goran Poje; Lidija Uzelac; Marijeta Kralj; Zrinka Rajić
Journal:  Molecules       Date:  2021-10-27       Impact factor: 4.411

3.  ChemVassa: A New Method for Identifying Small Molecule Hits in Drug Discovery.

Authors:  Brian Moldover; Ada Solidar; Christa Montgomery; Henry Miziorko; Jeff Murphy; Gerald J Wyckoff
Journal:  Open Med Chem J       Date:  2012-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.